This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

4 Jan 2016

Acerus terminates Natesto agreement with Endo

Acerus's immediate focus is to find a new Natesto partner in the US.

Acerus Pharmaceuticals Corporation has announced that the agreement with Endo Ventures Bermuda Limited (an affiliate of Endo International plc) relating to the commercialization of Natesto in the US and Mexico will be terminated, effective 30 June 2016.

Under the terms of the agreement with Acerus, Endo will continue to sell and distribute Natesto in the US until the effective date of termination.

Natesto is the first and only testosterone nasal gel to be approved and launched in the US for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.

“While we are disappointed with Endo’s previously announced strategic business decision to realign their US branded resources from urology retail to their pain franchise, we are fully committed to the continued success of Natesto in the US,” said Tom Rossi, President and Chief Executive Officer of Acerus. “Our immediate focus is on finding a new Natesto partner in the US, the largest market for testosterone replacement therapy. We are encouraged by the positive physician and patient feedback received on the product to date, and believe there will be strong interest from other companies to step in and continue to drive the launch of Natesto.”

Related News